These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 32576126)

  • 1. Effects and Mechanisms of Anlotinib and Dihydroartemisinin Combination Therapy in Ameliorating Malignant Biological Behavior of Gastric Cancer Cells.
    Luo Q; Zhang S; Zhang D; Feng R; Li N; Chen W; Chen X; Yang S
    Curr Pharm Biotechnol; 2021; 22(4):523-533. PubMed ID: 32576126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of onconase and dihydroartemisinin synergistically suppresses growth and angiogenesis of non-small-cell lung carcinoma and malignant mesothelioma.
    Shen R; Li J; Ye D; Wang Q; Fei J
    Acta Biochim Biophys Sin (Shanghai); 2016 Oct; 48(10):894-901. PubMed ID: 27590062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of Dihydroartemisinin on the Malignancy and Epithelial-Mesenchymal Transition of Gastric Cancer Cells.
    Li N; Zhang S; Luo Q; Yuan F; Feng R; Chen X; Yang S
    Curr Pharm Biotechnol; 2019; 20(9):719-726. PubMed ID: 31187708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway.
    Xu P; Wang H; Pan H; Chen J; Deng C
    Cancer Chemother Pharmacol; 2022 Feb; 89(2):183-196. PubMed ID: 34997858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dihydroartemisinin inhibits the tumorigenesis and invasion of gastric cancer by regulating STAT1/KDR/MMP9 and P53/BCL2L1/CASP3/7 pathways.
    Liang R; Chen W; Chen XY; Fan HN; Zhang J; Zhu JS
    Pathol Res Pract; 2021 Feb; 218():153318. PubMed ID: 33370709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-cancer activity of DHA on gastric cancer--an in vitro and in vivo study.
    Sun H; Meng X; Han J; Zhang Z; Wang B; Bai X; Zhang X
    Tumour Biol; 2013 Dec; 34(6):3791-800. PubMed ID: 23907579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel multi-target tyrosine kinase inhibitor anlotinib combined with irinotecan has in-vitro anti-tumor activity against human small-cell lung cancer.
    Li H; Liu Y; Liu X; Zhao D; Liu J; Cheng Y
    Anticancer Drugs; 2020 Nov; 31(10):1057-1064. PubMed ID: 32694423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First evidence that γ-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of NF-κB pathway.
    Manu KA; Shanmugam MK; Ramachandran L; Li F; Fong CW; Kumar AP; Tan P; Sethi G
    Clin Cancer Res; 2012 Apr; 18(8):2220-9. PubMed ID: 22351692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic Antitumor Effects of Anlotinib Combined with Oral 5-Fluorouracil/S-1 via Inhibiting Src/AKT Signaling Pathway in Small-Cell Lung Cancer.
    Xia X; Pi W; Lan Y; Wu X; Lv D; Meng Y; Yang H; Wang W
    Anal Cell Pathol (Amst); 2022; 2022():4484211. PubMed ID: 35757014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.
    Xie C; Wan X; Quan H; Zheng M; Fu L; Li Y; Lou L
    Cancer Sci; 2018 Apr; 109(4):1207-1219. PubMed ID: 29446853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dihydroartemisinin improves the efficiency of chemotherapeutics in lung carcinomas in vivo and inhibits murine Lewis lung carcinoma cell line growth in vitro.
    Zhou HJ; Zhang JL; Li A; Wang Z; Lou XE
    Cancer Chemother Pharmacol; 2010 May; 66(1):21-9. PubMed ID: 19756601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dihydroartemisinin inhibits the growth and invasion of gastric cancer cells by regulating cyclin D1-CDK4-Rb signaling.
    Fan HN; Zhu MY; Peng SQ; Zhu JS; Zhang J; Qu GQ
    Pathol Res Pract; 2020 Feb; 216(2):152795. PubMed ID: 31879047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma.
    Song F; Hu B; Cheng JW; Sun YF; Zhou KQ; Wang PX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
    Cell Death Dis; 2020 Jul; 11(7):573. PubMed ID: 32709873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo.
    Jaeger-Lansky A; Cejka D; Ying L; Preusser M; Hoeflmayer D; Fuereder T; Koehrer S; Wacheck V
    Cancer Biol Ther; 2010 Jun; 9(11):919-27. PubMed ID: 20404549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic effect of oxymatrine and angiogenesis inhibitor NM-3 on modulating apoptosis in human gastric cancer cells.
    Song MQ; Zhu JS; Chen JL; Wang L; Da W; Zhu L; Zhang WP
    World J Gastroenterol; 2007 Mar; 13(12):1788-93. PubMed ID: 17465467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anlotinib inhibits the progress of colorectal cancer cells by antagonizing VEGFR/JAK2/STAT3 axis.
    Jia ZX; Zhang Z; Li Z; Li A; Xie YN; Wu HJ; Yang ZB; Zhang HM; Zhang XM
    Eur Rev Med Pharmacol Sci; 2021 Mar; 25(5):2331-2343. PubMed ID: 33755971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anlotinib Inhibits Cell Proliferation, Migration and Invasion via Suppression of c-Met Pathway and Activation of ERK1/2 Pathway in H446 Cells.
    Tang X; Zheng Y; Jiao D; Chen J; Liu X; Xiong S; Chen Q
    Anticancer Agents Med Chem; 2021; 21(6):747-755. PubMed ID: 32682383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.
    Wang G; Sun M; Jiang Y; Zhang T; Sun W; Wang H; Yin F; Wang Z; Sang W; Xu J; Mao M; Zuo D; Zhou Z; Wang C; Fu Z; Wang Z; Duan Z; Hua Y; Cai Z
    Int J Cancer; 2019 Aug; 145(4):979-993. PubMed ID: 30719715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells.
    Liang L; Hui K; Hu C; Wen Y; Yang S; Zhu P; Wang L; Xia Y; Qiao Y; Sun W; Fei J; Chen T; Zhao F; Yang B; Jiang X
    J Exp Clin Cancer Res; 2019 Feb; 38(1):71. PubMed ID: 30755242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anlotinib suppresses proliferation, migration, and immune escape of gastric cancer cells by activating the cGAS-STING/IFN-β pathway.
    Yuan M; Guo XL; Chen JH; He Y; Liu ZQ; Zhang HP; Ren J; Xu Q
    Neoplasma; 2022 Jul; 69(4):807-819. PubMed ID: 35471977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.